BR112022013643A2 - TETRAHYDROISOQUINOLINE COMPOUND AS A POTASSIUM CHANNEL MODULATOR AND PREPARATION AND APPLICATION THEREOF - Google Patents

TETRAHYDROISOQUINOLINE COMPOUND AS A POTASSIUM CHANNEL MODULATOR AND PREPARATION AND APPLICATION THEREOF

Info

Publication number
BR112022013643A2
BR112022013643A2 BR112022013643A BR112022013643A BR112022013643A2 BR 112022013643 A2 BR112022013643 A2 BR 112022013643A2 BR 112022013643 A BR112022013643 A BR 112022013643A BR 112022013643 A BR112022013643 A BR 112022013643A BR 112022013643 A2 BR112022013643 A2 BR 112022013643A2
Authority
BR
Brazil
Prior art keywords
preparation
application
potassium channel
channel modulator
tetrahydroisoquinoline compound
Prior art date
Application number
BR112022013643A
Other languages
Portuguese (pt)
Inventor
Liang Bo
Liu Gang
Chen Huanming
Original Assignee
Shanghai Zhimeng Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Zhimeng Biopharma Inc filed Critical Shanghai Zhimeng Biopharma Inc
Publication of BR112022013643A2 publication Critical patent/BR112022013643A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

COMPOSTO DE TETRA-HIDROISOQUINOLINA COMO MODULADOR DE CANAL DE POTÁSSIO E PREPARAÇÃO E APLICAÇÃO DO MESMO. Um composto de tetra-hidroisoquinolina como um modulador de canal de potássio e preparação e aplicação do mesmo. Especificamente, o composto tem a estrutura como apresentada na fórmula A.TETRAHYDROISOQUINOLINE COMPOUND AS A POTASSIUM CHANNEL MODULATOR AND PREPARATION AND APPLICATION THEREOF. A tetrahydroisoquinoline compound as a potassium channel modulator and preparation and application thereof. Specifically, the compound has the structure as shown in formula A.

BR112022013643A 2020-08-07 2021-08-05 TETRAHYDROISOQUINOLINE COMPOUND AS A POTASSIUM CHANNEL MODULATOR AND PREPARATION AND APPLICATION THEREOF BR112022013643A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010790306.7A CN114057641A (en) 2020-08-07 2020-08-07 Tetrahydroisoquinoline compounds as potassium channel regulator and preparation and application thereof
PCT/CN2021/110991 WO2022028548A1 (en) 2020-08-07 2021-08-05 Tetrahydroisoquinoline compound as potassium channel modulator and preparation and application thereof

Publications (1)

Publication Number Publication Date
BR112022013643A2 true BR112022013643A2 (en) 2022-12-13

Family

ID=80117052

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022013643A BR112022013643A2 (en) 2020-08-07 2021-08-05 TETRAHYDROISOQUINOLINE COMPOUND AS A POTASSIUM CHANNEL MODULATOR AND PREPARATION AND APPLICATION THEREOF

Country Status (10)

Country Link
US (1) US20230077155A1 (en)
EP (1) EP4071138A4 (en)
JP (1) JP7458670B2 (en)
KR (1) KR20220116466A (en)
CN (2) CN114057641A (en)
AU (1) AU2021319662B2 (en)
BR (1) BR112022013643A2 (en)
CA (1) CA3163938A1 (en)
IL (1) IL294637A (en)
WO (1) WO2022028548A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116535354A (en) * 2022-01-25 2023-08-04 上海挚盟医药科技有限公司 Aromatic ring heterocyclic compound as potassium channel regulator, and preparation and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101563085A (en) * 2006-08-23 2009-10-21 威朗国际制药公司 Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
EA200900749A1 (en) * 2006-11-28 2009-12-30 Валеант Фармасьютикалс Интернэшнл 1,4-DIAMINOBICYCLIC ANALOGUES OF RETIGABIN AS MODULATORS OF POTASSIUM CHANNELS
MX2010001824A (en) * 2007-08-17 2010-04-21 Icagen Inc Heterocycles as potassium channel modulators.
CN103508960B (en) * 2012-06-29 2017-12-12 江苏先声药业有限公司 Benzheterocyclic derivatives
CN107108556B (en) * 2014-11-03 2020-09-29 艾欧米制药有限公司 Pharmaceutical compounds
CN107814785B (en) * 2016-09-14 2021-02-05 四川大学 Androgen receptor antagonist and preparation method and application thereof
CN110511220B (en) * 2018-05-22 2022-04-01 上海挚盟医药科技有限公司 P-diaminobenzene derivatives as potassium channel modulators, process for their preparation and their use in medicine

Also Published As

Publication number Publication date
EP4071138A1 (en) 2022-10-12
AU2021319662B2 (en) 2023-05-25
EP4071138A4 (en) 2023-07-19
CN114057641A (en) 2022-02-18
CN114845995A (en) 2022-08-02
KR20220116466A (en) 2022-08-23
CN114845995B (en) 2024-02-13
IL294637A (en) 2022-09-01
WO2022028548A1 (en) 2022-02-10
AU2021319662A1 (en) 2022-07-14
JP7458670B2 (en) 2024-04-01
US20230077155A1 (en) 2023-03-09
JP2023510233A (en) 2023-03-13
CA3163938A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
CL2020000594S1 (en) Headphone case.
MX2016001424A (en) Sweetener compositions.
BR112015000522A2 (en) absorbent insert with positioning notch
CL2016000106A1 (en) Sulfonamides as modulators of sodium channels.
EA201591474A1 (en) METHOL MODIFYING ENZYME MODULATORS, COMPOSITIONS AND THEIR APPLICATION
TWD201829S (en) Busbar-less solar cell
UA107791C2 (en) Pesticidal compositions
PH12015502546B1 (en) 3-(4-isobutyl-2-methylphenyl) propanal as perfume ingredient
UY31274A1 (en) ELECTRODEPOSITABLE COATING COMPOSITIONS CONTAINING A CYCLIC GUANIDINE
CL2008001756A1 (en) Interference RNA Agent (IARN); pharmaceutical composition comprising it; and its use to treat pathological processes mediated at least in part by the expression of the epithelial sodium channel alpha (alpha-enac)
CR10528A (en) PROCESS TO PRODUCE POXVIRUS AND POXVIRUS COMPOSITIONS
CR20170111A (en) CYTOTOXIC BENZODIAZEPIN DERIVATIVES
CO2021008980A2 (en) Achromosomal dynamic active systems
TR201907828T4 (en) AN ANTI-MICROBIAL AGENT WITH A WIDE SPECTRUM
BR0212233A (en) Chloride Channel Opener
MX2016007838A (en) Oral care compositions comprisng calcium carbonate and silica.
AR074270A1 (en) CONCENTRATED SHAMPOO COMPOSITION
BR112022013643A2 (en) TETRAHYDROISOQUINOLINE COMPOUND AS A POTASSIUM CHANNEL MODULATOR AND PREPARATION AND APPLICATION THEREOF
TWD201819S (en) Busbar-less solar cell
BR112018074742A2 (en) method and device for providing a backup link
AR104488A1 (en) NARROW INTERVAL ALCOHOL ALCOXYLATES AND DERIVATIVES OF THESE
MX2016003543A (en) Improved fibrous structures containing surfactants and methods for making the same.
MX2019005557A (en) Oral Care Composition.
CL2019001469S1 (en) Toothbrush.
BR112018010516A2 (en) oral care gel